FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT	OF CH	IANGES	IN BENE	EFICIAL	OWNER!	SHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average I	burden							
hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  LYANGEL THAT COTTINA D				2. Issuer Name <b>and</b> Ticker or Trading Symbol NABI BIOPHARMACEUTICALS [ NABI ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
LYNCH TIMOTHY P			-							_ [ 1.1.12	. ,	X Directo	or		10% Ov	/ner	
(Last)	`	irst) ARMACEUTICA	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/20/2010								Officer below)	(give title		Other (s below)	pecify
12276 WILKINS AVE			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6.	6. Individual or Joint/Group Filing (Check Applicable					
(Street)	ILLE M	D	20852					· ·			,	Lin	X Form f	iled by More		orting Person	
(City)	(S	tate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			. Transactio ate Month/Day/Y	Execution Date,		Code (Instr. 5)		ed (A) or tr. 3, 4 and	Benefici	es ally Following	Form y (D) or		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	v	Amount	(A) or (D)	Price	Transaci (Instr. 3	tion(s)			(o)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		Code	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$5.24	05/20/2010		A		20,000		(1)	C	95/20/2017	Common Stock	20,000	\$0	20,000		D	

## Explanation of Responses:

1. The Stock Option (right to buy) is exercisable in four equal installments on August 20, 2010, November 20, 2010, February 20, 2011, and May 20, 2011.

## Remarks:

<u>James E. Dawson, as attorney-in-fact</u> <u>05/24/2010</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.